Maranha, A., Moynihan, P. J., Miranda, V., Correia Lourenço, E., et al. (2015). Octanoylation of early intermediates of mycobacterial methylglucose lipopolysaccharides. Scientific Reports, 5.

Do Sameiro-Faria, M., Ribeiro, S., Rocha-Pereira, P., Fernandes, J., et al. (2013). Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients. Renal Failure, 35(10), 1392 - 1398.

Kohlova, M., Ribeiro, S., Do Sameiro-Faria, M., Rocha-Pereira, P., et al. (2013). Circulating cell-free DNA levels in hemodialysis patients and its association with inflammation, iron metabolism, and rhEPO doses. Hemodialysis International, 17(4), 664 - 667.

Ribeiro, S., Do Sameiro Faria, M., Mascarenhas-Melo, F., Freitas, I., et al. (2012). Main determinants of PON1 activity in hemodialysis patients. American Journal of Nephrology, 36(4), 317 - 323.

Costa, E., Coimbra, J., Catarino, C., Ribeiro, S., et al. (2012). Major determinants of BMP-2 serum levels in hemodialysis patients. Renal Failure, 34(10), 1355 - 1358.

Ribeiro, S., Faria, M. D. S., Silva, G., Nascimento, H., et al. (2012). Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: Influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene. Hemodialysis International, 16(4), 481 - 490.

Borges, A., Borges, M., Fernandes, J., Nascimento, H., et al. (2011). Apoptosis of peripheral CD4 ++ T-lymphocytes in end-stage renal disease patients under hemodialysis and rhEPO therapies. Renal Failure, 33(2), 138 - 143.

Pereira, R., Costa, E., Gonçalves, M., Miranda, V., et al. (2010). Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationship with resistance to recombinant human erythropoietin and to the hemodialysis procedure. Hemodialysis International, 14(3), 295 - 301.

Costa, E., Rocha, S., Rocha-Pereira, P., Reis, F., et al. (2009). Effect of hemodialysis procedure in prohepcidin serum levels in regular hemodialysis patients. Clinical Nephrology, 71(2), 233 - 235.

Costa, E., Swinkels, D. W., Laarakkers, C. M., Rocha-Pereira, P., et al. (2009). Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematologica, 122(4), 226 - 229.

Costa, E., Rocha, S., Rocha-Pereira, P., Castro, E., et al. (2008). Altered erythrocyte membrane protein composition in chronic kidney disease stage 5 patients under haemodialysis and recombinant human erythropoietin therapy. Blood Purification, 26(3), 267 - 273.

Costa, E., Rocha, S., Rocha-Pereira, P., Castro, E., et al. (2008). Changes in red blood cells membrane protein composition during hemodialysis procedure. Renal Failure, 30(10), 971 - 975.

Costa, E., Rocha, S., Rocha-Pereira, P., Castro, E., et al. (2008). Cross-talk between inflammation, coagulation/fibrinolysis and vascular access in hemodialysis patients. Journal of Vascular Access, 9(4), 248 - 253.

Costa, E., Rocha, S., Rocha-Pereira, P., Reis, F., et al. (2008). DMT1 (NRAMP2/DCT1) Genetic Variability and Resistance to Recombinant Human Erythropoietin Therapy in Chronic Kidney Disease Patients under Haemodialysis. Acta Haematologica, 120(1), 11 - 13.

Costa, E., Lima, M., Rocha, S., Rocha-Pereira, P., et al. (2008). IL-7 serum levels and lymphopenia in hemodialysis patients, non-responders to recombinant human erythropoietin therapy. Blood Cells, Molecules, and Diseases, 41(1), 134 - 135.

Costa, E., Lima, M., Alves, J. M., Rocha, S., et al. (2008). Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. Journal of Clinical Immunology, 28(3), 268 - 275.

Costa, E., Rocha, S., Rocha-Pereira, P., Nascimento, H., et al. (2008). Neutrophil activation and resistance to recombinant human erythropoietin therapy in hemodialysis patients. American Journal of Nephrology, 28(6), 935 - 940.

Costa, E., Pereira, B. J. G., Rocha-Pereira, P., Rocha, S., et al. (2008). Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. American Journal of Nephrology, 28(4), 677 - 683.